Kinase News and Research

RSS

Researchers find novel inhibitors that may suppress oncogenesis of metastatic prostate cancer

Researchers have found that treating prostate cancer cells with novel cyclin-dependent kinase 19 (CDK19) and homologous cyclin-dependent kinase 8 (CDK8) inhibitors reduces their potential to migrate into and invade surrounding structures.

13 Apr 2022

Reaction Biology's Novel Approach to Oncology Drug Discovery at AACR Showcase

Reaction Biology, an industry-leading provider of drug discovery services, today announced that twelve abstracts highlighting data from the Company's oncology drug discovery services platform will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022, in New Orleans, Louisiana.

From Reaction Biology Corporation 13 Apr 2022

The molecular context and substrate profiles of human cell surface receptor tyrosine kinases

researchers discussed and identified the systemic functions and interactions of 52 active cell surface receptor tyrosine kinases, providing insights on RTK-RTK interactions and substrates, RTK-protein complexes, and signaling pathways.

13 Apr 2022

Epigenetics likely to be the reason why lung cancer patients develop treatment resistance

Doctors typically treat people with nonsmall cell lung cancer, a prevalent and typically incurable type of cancer that makes up 80%-85% of lung cancers, with tyrosine kinase inhibitors, specifically epidermal growth factor receptor inhibitors.

13 Apr 2022

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

In a new study, researchers quantified the serological responses following the third dose of mRNA-based COVID-19 vaccines in patients with hematological malignancies.

12 Apr 2022

Researchers elucidate how ovarian tumors defy immunotherapy

Researchers at University of California San Diego School of Medicine and Moores Cancer Center at UC San Diego Health, with collaborators at La Jolla Institute for Immunology and elsewhere, have further elucidated how ovarian cancer tumors defy immunotherapy, identifying new molecular targets that might boost immune response.

12 Apr 2022

Scientists find critical role for Hippo signaling pathway in COVID-19 pathogenesis

A recent article posted to the bioRxiv* preprint server illustrated that the activation of the Hippo signaling pathway upon severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection aids the host antiviral response.

11 Apr 2022

Discovery of key regulator of body weight could lead to new treatments for metabolic disorders

Yale scientists uncover key regulator of body weight. Yale scientists have discovered that a protein known as augmentor-alpha regulates body weight in mice, an insight that could lead to new treatments for metabolic disorders.

11 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Exploring evolutionary trajectories of SARS-CoV-2 interacting proteins in bats and primates

Researchers performed high-throughput evolutionary analyses of genes encoding 334 SARS-CoV-2 viral-interacting proteins of modern humans, primates, and bats.

11 Apr 2022

Sodium thiosulfate shows no benefits for reducing heart damage following a heart attack

Sodium thiosulfate showed no benefits for reducing injury to damaged areas of heart muscle following a heart attack, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

5 Apr 2022

Study investigates targeted phenotyping of host proteins aiding drug repurposing in COVID-19

Researchers conducted selective phenotyping of coronavirus disease 2019 -relevant host proteins to facilitate target identification for drug repurposing.

4 Apr 2022

TLR7 and MARK1 genomic variants impact COVID-19 prognosis

Researchers conduct a massive exome-wide genome study to explore the connections between gene variants/deleterious mutations and COVID-19 outcomes.

3 Apr 2022

Virginia Tech researcher awarded $1.9 million grant to study about mitophagy

Most of us remember enough biology to recall that mitochondria are known as "the powerhouse of the cell." Even that audacious term may downplay the importance of mitochondria and what happens when mitochondria go bad.

31 Mar 2022

Decisive role of PDK1 enzyme in acute myeloid leukemia revealed

Acute myeloid leukemia (AML) remains harder to treat therapeutically due to the high existing genetic heterogeneity not only between patients but also between the population of subclones of cancer cells within the same person.

30 Mar 2022

New tactic to disrupt cancer repair mechanism could lead to a potential treatment strategy

While cancer therapies targeting specific genes or disease pathways have extended lives, they can also lead to highly resistant tumors when small reservoirs of cancer cells survive treatment, grow, and spread.

30 Mar 2022

A ferritin nanoparticle candidate vaccine for COVID

In a recent study published on the bioRxiv* preprint server, the immunogenicity, and effectiveness of SARS-CoV-2 spike ferritin nanoparticle (SpFN) adjuvanted with aluminum hydroxide (AlOH3) or Army Liposomal Formulation QS-21 (ALFQ) in a cynomolgus macaque (CM) COVID-19 model was evaluated.

30 Mar 2022

CDK6: a potential drug target for severe COVID-19

Researchers identify a methodology and workflow to repurpose drugs against the cyclin-dependent kinase 6 target gene of SARS-CoV-2.

27 Mar 2022

Prevalence of organ impairment in Long COVID patients 6 and 12 months after initial symptoms

Researchers assessed the prevalence of organ impairment in long COVID six months and a year post-COVID-19 at London and Oxford.

24 Mar 2022

TTUHSC researcher secures $1.9 million grant to investigate vulnerabilities in ALT cancers

The National Cancer Institute, part of the National Institutes of Health, recently awarded a five-year, $ $1.9 million grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at the Texas Tech University Health Sciences Center.

23 Mar 2022

Kinase News and Research

Researchers find novel inhibitors that may suppress oncogenesis of metastatic prostate cancer

Reaction Biology's Novel Approach to Oncology Drug Discovery at AACR Showcase

The molecular context and substrate profiles of human cell surface receptor tyrosine kinases

Epigenetics likely to be the reason why lung cancer patients develop treatment resistance

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

Researchers elucidate how ovarian tumors defy immunotherapy

Scientists find critical role for Hippo signaling pathway in COVID-19 pathogenesis

Discovery of key regulator of body weight could lead to new treatments for metabolic disorders

New study reveals oral opaganib's potent in vitro activity against Omicron

Exploring evolutionary trajectories of SARS-CoV-2 interacting proteins in bats and primates

Sodium thiosulfate shows no benefits for reducing heart damage following a heart attack

Study investigates targeted phenotyping of host proteins aiding drug repurposing in COVID-19

TLR7 and MARK1 genomic variants impact COVID-19 prognosis

Virginia Tech researcher awarded $1.9 million grant to study about mitophagy

Decisive role of PDK1 enzyme in acute myeloid leukemia revealed

New tactic to disrupt cancer repair mechanism could lead to a potential treatment strategy

A ferritin nanoparticle candidate vaccine for COVID

CDK6: a potential drug target for severe COVID-19

Prevalence of organ impairment in Long COVID patients 6 and 12 months after initial symptoms

TTUHSC researcher secures $1.9 million grant to investigate vulnerabilities in ALT cancers

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News